$CLNN
Clene Inc. Stock $clnn

$clnn Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-K Financial Statement

#000095017022003410 Filed on March 11, 2022

Income Statement

Concept	2022 Q1	2021 Q4	2021
Revenue	$30.00K	$199.0K	$723.0K
YoY Change	-85.92%	-5.24%	250.97%
Cost Of Revenue	$0.00	-$523.0K	$289.0K
YoY Change	-100.0%	-5330.0%	312.86%
Gross Profit	$30.00K	$722.0K	$434.0K
YoY Change	-200.0%	3510.0%	210.0%
Gross Profit Margin	100.0%	362.81%	60.03%
Selling, General & Admin	$4.757M	$5.257M	$21.90M
YoY Change	-8.34%	24.87%	333.58%
% of Gross Profit	15856.67%	728.12%	5045.16%
Research & Development	$8.580M	$9.323M	$28.42M
YoY Change	36.73%	136.03%	86.9%
% of Gross Profit	28600.0%	1291.27%	6547.47%
Depreciation & Amortization	$195.0K	$221.0K	$955.0K
YoY Change	-20.08%	-76.98%	-0.83%
% of Gross Profit	650.0%	30.61%	220.05%
Operating Expenses	$13.37M	$14.78M	$50.70M
YoY Change	12.24%	-26.54%	148.29%
Operating Profit	-$13.34M	-$14.06M	-$49.98M
YoY Change	14.03%	-30.06%	147.24%
Interest Expense	$782.0K	$15.51M	$870.0K
YoY Change	41.92%	20.87%	-8.42%
% of Operating Profit
Other Income/Expense, Net	-$18.00K	$2.757M	$39.81M
YoY Change	-99.94%	-124.38%	2864.26%
Pretax Income	-$13.35M	$4.208M	-$10.17M
YoY Change	-66.47%	-122.87%	-46.12%
Income Tax	$0.00	-$215.0K	-$428.0K
% Of Pretax Income		-5.11%
Net Earnings	-$13.35M	$4.423M	-$9.740M
YoY Change	-66.41%	-123.51%	-49.47%
Net Earnings / Revenue	-44513.33%	2222.61%	-1347.16%
Basic Earnings Per Share	-$0.21		-$0.16
Diluted Earnings Per Share	-$212.5K	$70.98K	-$158.2K
COMMON SHARES
Basic Shares Outstanding	63.14M		61.56M
Diluted Shares Outstanding

Balance Sheet

Concept	2022 Q1	2021 Q4	2021
SHORT-TERM ASSETS
Cash & Short-Term Investments	$36.52M	$50.29M	$50.29M
YoY Change	-23.99%	-15.17%	-15.17%
Cash & Equivalents	$12.90M	$50.29M
Short-Term Investments	$23.59M
Other Short-Term Assets	$3.978M	$2.641M	$2.641M
YoY Change	64.38%	95.63%	95.63%
Inventory	$38.00K	$41.00K	$41.00K
Prepaid Expenses	$5.895M	$4.205M
Receivables		$49.00K	$49.00K
Other Receivables	$1.917M	$1.564M	$1.564M
Total Short-Term Assets	$42.45M	$54.58M	$54.58M
YoY Change	-20.42%	-13.35%	-13.35%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.914M	$5.172M	$8.422M
YoY Change	13.95%	22.41%	60.42%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$58.00K	$58.00K	$58.00K
YoY Change
Total Long-Term Assets	$10.91M	$8.480M	$8.480M
YoY Change	110.25%	61.4%	61.52%
TOTAL ASSETS
Total Short-Term Assets	$42.45M	$54.58M	$54.58M
Total Long-Term Assets	$10.91M	$8.480M	$8.480M
Total Assets	$53.36M	$63.06M	$63.06M
YoY Change	-8.83%	-7.59%	-7.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.313M	$1.923M	$1.923M
YoY Change	347.7%	71.09%	71.7%
Accrued Expenses	$1.541M	$3.610M	$3.957M
YoY Change	-47.41%	-8.84%	-4.65%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$139.0K	$146.0K	$146.0K
YoY Change	-0.71%	-23.16%	-23.16%
Total Short-Term Liabilities	$5.466M	$6.026M	$6.026M
YoY Change	33.64%	-48.35%	-48.36%
LONG-TERM LIABILITIES
Long-Term Debt	$19.44M	$19.18M	$19.18M
YoY Change	848.24%	792.05%	792.05%
Other Long-Term Liabilities	$26.44M	$25.26M	$25.26M
YoY Change	-70.04%	-53.06%	-53.06%
Total Long-Term Liabilities	$45.88M	$44.44M	$44.44M
YoY Change	-49.19%	-20.6%	-20.6%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.466M	$6.026M	$6.026M
Total Long-Term Liabilities	$45.88M	$44.44M	$44.44M
Total Liabilities	$51.34M	$50.47M	$50.47M
YoY Change	-45.73%	-25.68%	-25.68%
SHAREHOLDERS EQUITY
Retained Earnings	-$176.7M	-$163.3M
YoY Change		6.34%
Common Stock	$6.000K	$6.000K
YoY Change		0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.017M	$12.60M	$12.60M
YoY Change
Total Liabilities & Shareholders Equity	$53.36M	$63.06M	$63.06M
YoY Change	-8.83%	-7.59%	-7.59%

Cashflow Statement

Concept	2022 Q1	2021 Q4	2021
OPERATING ACTIVITIES
Net Income	-$13.35M	$4.423M	-$9.740M
YoY Change	-66.41%	-123.51%	-49.47%
Depreciation, Depletion And Amortization	$195.0K	$221.0K	$955.0K
YoY Change	-20.08%	-76.98%	-0.83%
Cash From Operating Activities	-$13.10M	-$9.606M	-$34.60M
YoY Change	42.39%	-47.02%	83.07%
INVESTING ACTIVITIES
Capital Expenditures	$936.0K	-$671.0K	$1.332M
YoY Change	361.08%	72.05%	244.19%
Acquisitions
YoY Change
Other Investing Activities	-$23.59M
YoY Change
Cash From Investing Activities	-$24.52M	-$671.0K	-$1.332M
YoY Change	11979.8%	72.05%	244.19%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	235.0K	-18.00K	27.11M
YoY Change	-112.39%	-100.03%	-61.01%
NET CHANGE
Cash From Operating Activities	-13.10M	-9.606M	-34.60M
Cash From Investing Activities	-24.52M	-671.0K	-1.332M
Cash From Financing Activities	235.0K	-18.00K	27.11M
Net Change In Cash	-37.36M	-10.30M	-8.929M
YoY Change	232.54%	-120.51%	-117.69%
FREE CASH FLOW
Cash From Operating Activities	-$13.10M	-$9.606M	-$34.60M
Capital Expenditures	$936.0K	-$671.0K	$1.332M
Free Cash Flow	-$14.04M	-$8.935M	-$35.93M
YoY Change	49.27%	-49.63%	86.3%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	761000
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001822791
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	clnn	Convertible Stock Warrants ConvertibleStockWarrants	0
CY2018Q3	clnn	Exclusive Rights Intellectual Property Term ExclusiveRightsIntellectualPropertyTerm	P5Y
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q4	clnn	Accrued Transaction Costs AccruedTransactionCosts
CY2021	clnn	Weighted Average Remaining Term Years Exercised WeightedAverageRemainingTermYearsExercised
CY2020Q4	clnn	Directors Officers Insurance DirectorsOfficersInsurance
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3502000
CY2021	clnn	Weighted Average Remaining Term Years Forfeited WeightedAverageRemainingTermYearsForfeited
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	01-39834
CY2021	dei	Entity Registrant Name EntityRegistrantName	CLENE INC.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-2828339
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	6550 South Millrock Drive
CY2021	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite G50
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Salt Lake City
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	UT
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	84121
CY2021	dei	City Area Code CityAreaCode	801
CY2021	dei	Local Phone Number LocalPhoneNumber	676 9695
CY2021	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value
CY2021	dei	Trading Symbol TradingSymbol	CLNN
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	true
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2021	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	359600000
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	63138351
CY2021	dei	Auditor Firm AuditorFirmId	34
CY2020	dei	Auditor Firm AuditorFirmId	238
CY2021	dei	Auditor Name AuditorName	Deloitte & Touche LLP
CY2021	dei	Auditor Location AuditorLocation	Salt Lake City, Utah
CY2020	dei	Auditor Name AuditorName	PricewaterhouseCoopers LLP
CY2020	dei	Auditor Location AuditorLocation	Salt Lake City, Utah
CY2021Q4	us-gaap	Cash Cash	50288000
CY2020Q4	us-gaap	Cash Cash	59275000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	49000
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	21000
CY2021Q4	us-gaap	Inventory Net InventoryNet	41000
CY2020Q4	us-gaap	Inventory Net InventoryNet	191000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4205000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	54583000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	62989000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	58000
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	0
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3250000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1029000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5172000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4225000
CY2021Q4	us-gaap	Assets Assets	63063000
CY2020Q4	us-gaap	Assets Assets	68243000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1923000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1124000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3610000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3960000
CY2021Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	0
CY2020Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	164000
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	0
CY2020Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	112000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	347000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	194000
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	146000
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	190000
CY2021Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0
CY2020Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	5924000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6026000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11668000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4370000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1785000
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	97000
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	205000
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	14484000
CY2020Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	1949000
CY2021Q4	clnn	Convertible Note Payable ConvertibleNotePayable	4598000
CY2020Q4	clnn	Convertible Note Payable ConvertibleNotePayable	0
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	0
CY2020Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	260000
CY2021Q4	clnn	Common Stock Warrant Liability CommonStockWarrantLiability	474000
CY2020Q4	clnn	Common Stock Warrant Liability CommonStockWarrantLiability	0
CY2021Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	18100000
CY2020Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	46129000
CY2021Q4	clnn	Initial Shareholders Contingent Earnout InitialShareholdersContingentEarnout	2317000
CY2020Q4	clnn	Initial Shareholders Contingent Earnout InitialShareholdersContingentEarnout	5906000
CY2021Q4	us-gaap	Liabilities Liabilities	50466000
CY2020Q4	us-gaap	Liabilities Liabilities	67902000
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	62312097
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	62312097
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	325000
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	59526171
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	59526171
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	6000
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	6000
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	175659000
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	153571000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-163301000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-153561000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	233000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	63063000
CY2021	us-gaap	Revenues Revenues	723000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	12597000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	68243000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	341000
CY2020	us-gaap	Revenues Revenues	206000
CY2021	clnn	Costs Of Revenue CostsOfRevenue	289000
CY2020	clnn	Costs Of Revenue CostsOfRevenue	65000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	28416000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15204000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	21996000
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5151000
CY2021	us-gaap	Operating Expenses OperatingExpenses	50701000
CY2020	us-gaap	Operating Expenses OperatingExpenses	20420000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-49978000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-20214000
CY2021	us-gaap	Interest Expense InterestExpense	870000
CY2020	us-gaap	Interest Expense InterestExpense	950000
CY2021	clnn	Gain On Extinguishment Of Notes Payable GainOnExtinguishmentOfNotesPayable	-648000
CY2020	clnn	Gain On Extinguishment Of Notes Payable GainOnExtinguishmentOfNotesPayable	-0
CY2021	clnn	Loss On Extinguishment Of Convertible Notes Payable LossOnExtinguishmentOfConvertibleNotesPayable	0
CY2020	clnn	Loss On Extinguishment Of Convertible Notes Payable LossOnExtinguishmentOfConvertibleNotesPayable	540000
CY2021	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	0
CY2020	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	51000
CY2021	clnn	Change In Fair Value Of Preferred Stock Warrant Liability ChangeInFairValueOfPreferredStockWarrantLiability	0
CY2020	clnn	Change In Fair Value Of Preferred Stock Warrant Liability ChangeInFairValueOfPreferredStockWarrantLiability	-14615000
CY2021	clnn	Change In Fair Value Of Common Stock Warrant Liability ChangeInFairValueOfCommonStockWarrantLiability	983000
CY2020	clnn	Change In Fair Value Of Common Stock Warrant Liability ChangeInFairValueOfCommonStockWarrantLiability	0
CY2021	us-gaap	Unrealized Gain Loss On Derivatives And Commodity Contracts UnrealizedGainLossOnDerivativesAndCommodityContracts	0
CY2020	us-gaap	Unrealized Gain Loss On Derivatives And Commodity Contracts UnrealizedGainLossOnDerivativesAndCommodityContracts	29000
CY2021	clnn	Change In Fair Value Of Contingent Earnout ChangeInFairValueOfContingentEarnout	33953000
CY2020	clnn	Change In Fair Value Of Contingent Earnout ChangeInFairValueOfContingentEarnout	12659000
CY2021	clnn	Change In Fair Value Of Initial Shareholders Contingent Earnout ChangeInFairValueOfInitialShareholdersContingentEarnout	3589000
CY2020	clnn	Change In Fair Value Of Initial Shareholders Contingent Earnout ChangeInFairValueOfInitialShareholdersContingentEarnout	1465000
CY2021	clnn	Australia Research And Development Credit AustraliaResearchAndDevelopmentCredit	-1519000
CY2020	clnn	Australia Research And Development Credit AustraliaResearchAndDevelopmentCredit	-3210000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-12000
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	34000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	39810000
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1343000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10168000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-18871000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-428000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	406000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-9740000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-19277000
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-92000
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	284000
CY2021	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	92000
CY2020	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-284000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9832000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18993000
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.16
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.10
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	61558455
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	17503992
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-67774000
CY2020	clnn	Stock Issued During Period Of Series D Preferred Stock StockIssuedDuringPeriodOfSeriesDPreferredStock	0
CY2020	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	0
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	78000
CY2020	clnn	Conversion Of Redeemable Convertible Preferred Stock Into Common Stock In Connection With The ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithThe	114603000
CY2020	clnn	Extinguishment Of Preferred Stock Warrant Liability In Connection With The Conversion Of Redeemable ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemable	17828000
CY2020	clnn	Issuance Of Common Stock In Connection With The Private Placement Offering Net Of Offering Costs IssuanceOfCommonStockInConnectionWithThePrivatePlacementOfferingNetOfOfferingCosts	31833000
CY2020	clnn	Stock Issued During Period Value Reverse Recapitalization Offering Costs StockIssuedDuringPeriodValueReverseRecapitalizationOfferingCosts	-5911000
CY2020	clnn	Issuance Of Common Stock As Payment Of Related Offering Costs IssuanceOfCommonStockAsPaymentOfRelatedOfferingCosts	0
CY2020	clnn	Contingent Earnout Recognized In Connection With Reverse Recapitalizati ContingentEarnoutRecognizedInConnectionWithReverseRecapitalizati	-64713000
CY2020	clnn	Contingent Earnout Recognized In Connection With The Reverse Recapitalization ContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization	-7371000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	761000
CY2020	clnn	Foreign Currency Translation Adjustment ForeignCurrencyTranslationAdjustment	284000
CY2020	us-gaap	Profit Loss ProfitLoss	-19277000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	341000
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	9250000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	443000
CY2021	clnn	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	11000
CY2021	clnn	Stock Issued During Period Exercise Of Underwriters Option StockIssuedDuringPeriodExerciseOfUnderwritersOption	0
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12384000
CY2021	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	0
CY2021	clnn	Foreign Currency Translation Adjustment ForeignCurrencyTranslationAdjustment	-92000
CY2021	us-gaap	Profit Loss ProfitLoss	-9740000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	12597000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-9740000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-19277000
CY2021	us-gaap	Depreciation Depreciation	955000
CY2020	us-gaap	Depreciation Depreciation	963000
CY2021	us-gaap	Other Noncash Expense OtherNoncashExpense	171000
CY2020	us-gaap	Other Noncash Expense OtherNoncashExpense	108000
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	14615000
CY2021	clnn	Change In Fair Value Of Common Stock Warrant Liability ChangeInFairValueOfCommonStockWarrantLiability	983000
CY2020	clnn	Change In Fair Value Of Common Stock Warrant Liability ChangeInFairValueOfCommonStockWarrantLiability	0
CY2021	clnn	Change In Fair Value Of Contingent Earnout ChangeInFairValueOfContingentEarnout	33953000
CY2020	clnn	Change In Fair Value Of Contingent Earnout ChangeInFairValueOfContingentEarnout	12659000
CY2021	clnn	Change In Fair Value Of Initial Shareholders Contingent Earnout ChangeInFairValueOfInitialShareholdersContingentEarnout	3589000
CY2020	clnn	Change In Fair Value Of Initial Shareholders Contingent Earnout ChangeInFairValueOfInitialShareholdersContingentEarnout	1465000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	12384000
CY2021	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	0
CY2020	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	29000
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	648000
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2021	clnn	Loss On Extinguishment Of Convertible Notes Payable LossOnExtinguishmentOfConvertibleNotesPayable	0
CY2020	clnn	Loss On Extinguishment Of Convertible Notes Payable LossOnExtinguishmentOfConvertibleNotesPayable	540000
CY2021	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	0
CY2020	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	51000
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	336000
CY2020	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	179000
CY2021	clnn	Increase Decrease In Fair Value Of Notes Payable IncreaseDecreaseInFairValueOfNotesPayable	-560000
CY2020	clnn	Increase Decrease In Fair Value Of Notes Payable IncreaseDecreaseInFairValueOfNotesPayable	732000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	28000
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	21000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-150000
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	163000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	702000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2841000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1267000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-312000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	894000
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-272000
CY2021	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	164000
CY2020	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	164000
CY2021	clnn	Increase Decrease In Payable To Related Parties IncreaseDecreaseInPayableToRelatedParties	0
CY2020	clnn	Increase Decrease In Payable To Related Parties IncreaseDecreaseInPayableToRelatedParties	-131000
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0
CY2020	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	112000
CY2021	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	260000
CY2020	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-260000
CY2021	clnn	Increase Decrease Operating Lease Obligations IncreaseDecreaseOperatingLeaseObligations	154000
CY2020	clnn	Increase Decrease Operating Lease Obligations IncreaseDecreaseOperatingLeaseObligations	142000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-34624000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18929000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1332000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	387000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1332000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-387000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	443000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	78000
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	11000
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	152000
CY2020	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	194000
CY2021	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	20000000
CY2020	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	652000
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	534000
CY2020	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	5000
CY2020	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0
CY2021	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	9250000
CY2020	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1901000
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	4011000
CY2021	clnn	Proceeds From The Private Placement Offering Net Of Offering Costs ProceedsFromThePrivatePlacementOfferingNetOfOfferingCosts	0
CY2020	clnn	Proceeds From The Private Placement Offering Net Of Offering Costs ProceedsFromThePrivatePlacementOfferingNetOfOfferingCosts	31833000
CY2021	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0
CY2020	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	35051000
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0
CY2020	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	6125000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	27112000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	69534000
CY2021	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-85000
CY2020	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	269000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-8929000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	50487000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	59275000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8788000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	50346000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	59275000
CY2021Q4	us-gaap	Cash Cash	50288000
CY2020Q4	us-gaap	Cash Cash	59275000
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	58000
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	0
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	50346000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	59275000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2892000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	820000
CY2021	clnn	Common Stock Warrant Liability Recorded At Issuance Of Notes Payable CommonStockWarrantLiabilityRecordedAtIssuanceOfNotesPayable	1457000
CY2020	clnn	Common Stock Warrant Liability Recorded At Issuance Of Notes Payable CommonStockWarrantLiabilityRecordedAtIssuanceOfNotesPayable	0
CY2021	clnn	Lease Liability Settled Through Termination Of Lease LeaseLiabilitySettledThroughTerminationOfLease	0
CY2020	clnn	Lease Liability Settled Through Termination Of Lease LeaseLiabilitySettledThroughTerminationOfLease	348000
CY2021	clnn	Issuance Of Derivative Instrument Related To Convertible Notes IssuanceOfDerivativeInstrumentRelatedToConvertibleNotes	0
CY2020	clnn	Issuance Of Derivative Instrument Related To Convertible Notes IssuanceOfDerivativeInstrumentRelatedToConvertibleNotes	705000
CY2021	clnn	Issuance Of Series D Preferred Stock Upon Extinguishment Of Convertible Promissory Notes IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes	0
CY2020	clnn	Issuance Of Series D Preferred Stock Upon Extinguishment Of Convertible Promissory Notes IssuanceOfSeriesDPreferredStockUponExtinguishmentOfConvertiblePromissoryNotes	5675000
CY2021	clnn	Extinguishment Of Derivative Liability In Connection With Extinguishment Of Convertible Promissory N ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN	0
CY2020	clnn	Extinguishment Of Derivative Liability In Connection With Extinguishment Of Convertible Promissory N ExtinguishmentOfDerivativeLiabilityInConnectionWithExtinguishmentOfConvertiblePromissoryN	676000
CY2021	clnn	Deferred Transaction Costs In Accounts Payable DeferredTransactionCostsInAccountsPayable	0
CY2020	clnn	Deferred Transaction Costs In Accounts Payable DeferredTransactionCostsInAccountsPayable	546000
CY2021	clnn	Deferred Transactions Costs In Accrued Liabilities DeferredTransactionsCostsInAccruedLiabilities	0
CY2020	clnn	Deferred Transactions Costs In Accrued Liabilities DeferredTransactionsCostsInAccruedLiabilities	1354000
CY2021	clnn	Conversion Of Redeemable Convertible Preferred Stock Into Common Stock ConversionOfRedeemableConvertiblePreferredStockIntoCommonStock	0
CY2020	clnn	Conversion Of Redeemable Convertible Preferred Stock Into Common Stock ConversionOfRedeemableConvertiblePreferredStockIntoCommonStock	114603000
CY2021	clnn	Extinguishment Of Preferred Stock Warrant Liability In Connection With The Conversion Of Redeemable Convertible Sreferred Stock ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemableConvertibleSreferredStock	0
CY2020	clnn	Extinguishment Of Preferred Stock Warrant Liability In Connection With The Conversion Of Redeemable Convertible Sreferred Stock ExtinguishmentOfPreferredStockWarrantLiabilityInConnectionWithTheConversionOfRedeemableConvertibleSreferredStock	17828000
CY2021	clnn	Issuance Of Common Stock As Payment Related Offering Costs IssuanceOfCommonStockAsPaymentRelatedOfferingCosts	0
CY2020	clnn	Issuance Of Common Stock As Payment Related Offering Costs IssuanceOfCommonStockAsPaymentRelatedOfferingCosts	6442000
CY2021	clnn	Contingent Earnout Recognized Connection With The Reverse Recapitalization ContingentEarnoutRecognizedConnectionWithTheReverseRecapitalization	0
CY2020	clnn	Contingent Earnout Recognized Connection With The Reverse Recapitalization ContingentEarnoutRecognizedConnectionWithTheReverseRecapitalization	64713000
CY2021	clnn	Initial Shareholders Contingent Earnout Recognized In Connection With The Reverse Recapitalization InitialShareholdersContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization	0
CY2020	clnn	Initial Shareholders Contingent Earnout Recognized In Connection With The Reverse Recapitalization InitialShareholdersContingentEarnoutRecognizedInConnectionWithTheReverseRecapitalization	7371000
CY2021	clnn	Cash Paid For Interest Expense CashPaidForInterestExpense	1095000
CY2020	clnn	Cash Paid For Interest Expense CashPaidForInterestExpense	39000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-50000000.0
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-20200000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-9700000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-19300000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-163300000
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	50300000
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	59300000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-34600000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18900000
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q1	clnn	Aggregate Future Proceeds Warrants Exercised AggregateFutureProceedsWarrantsExercised	30700000
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.01
CY2021Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1140731
CY2021Q3	clnn	Common Stock Underlying Warrant Outstanding CommonStockUnderlyingWarrantOutstanding	1024880
CY2021Q2	clnn	Common Stock Underlying Warrant Outstanding CommonStockUnderlyingWarrantOutstanding	115851
CY2021Q3	clnn	Aggregate Future Proceeds Warrants Exercised AggregateFutureProceedsWarrantsExercised	3000000.0
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and disclosure of contingent assets and liabilities, and the reported amounts of expenses. We base our estimates on historical experience and various other assumptions that we believe to be reasonable. Actual results may differ from those estimates or assumptions. Estimates are periodically reviewed in light of changes in circumstances, facts, and experience, and any changes in estimates will be recorded in future periods as they develop.</span></p>
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentrations of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments which potentially subject us to significant concentrations of credit risk consist primarily of cash. Our cash is mainly held in financial institutions. Amounts on deposit may at times exceed federally insured limits. We have not experienced any losses on our deposits of cash and do not believe that we are subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></p>
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	100000
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	0
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	26308
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	14391
CY2020Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	71290
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	119275
CY2021Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	0
CY2020Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	5900000
CY2020	clnn	Grant Funding Recognized On Conditional Grants GrantFundingRecognizedOnConditionalGrants	800000
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	0
CY2020Q4	us-gaap	Deferred Revenue DeferredRevenue	100000
CY2021	clnn	Grant Funding Recognized On Conditional Grants GrantFundingRecognizedOnConditionalGrants	200000
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2
CY2020Q4	clnn	Proceeds From Reverse Recapitalization ProceedsFromReverseRecapitalization	9400000
CY2020Q4	clnn	Net Proceeds From Reverse Recapitalization NetProceedsFromReverseRecapitalization	3500000
CY2020Q4	us-gaap	Other Underwriting Expense OtherUnderwritingExpense	2100000
CY2021	clnn	Clenenanomedicinecontingentearnoutmilestone1 Shares Clenenanomedicinecontingentearnoutmilestone1Shares	3333333
CY2021	clnn	Clenenanomedicinecontingentearnoutmilestone1 Price Clenenanomedicinecontingentearnoutmilestone1Price	15.00
CY2021	clnn	Clenenanomedicinecontingentearnoutmilestone2 Shares Clenenanomedicinecontingentearnoutmilestone2Shares	2500000
CY2021	clnn	Clene Nanomedicine Contingent Earnout Milestone2 Price CleneNanomedicineContingentEarnoutMilestone2Price	20.00
CY2021	clnn	Clene Nanomedicine Contingent Earnout Milestone3 Shares CleneNanomedicineContingentEarnoutMilestone3Shares	2500000
CY2021	clnn	Increase In Clene Nanomedicine Contingent Earnout Shares Upon Reverse Recapitalization IncreaseInCleneNanomedicineContingentEarnoutSharesUponReverseRecapitalization	12852
CY2021	clnn	Total Clene Nanomedicine Contingent Earnout Shares TotalCleneNanomedicineContingentEarnoutShares	8346185
CY2021	clnn	Initial Shareholders Contingent Earnout Milestone One Shares InitialShareholdersContingentEarnoutMilestoneOneShares	375000
CY2021	clnn	Initial Shareholders Contingent Earnout Milestone2 Shares InitialShareholdersContingentEarnoutMilestone2Shares	375000
CY2021Q4	clnn	Clene Nanomedicine Contingent Earnout Milestone Three Shares Cancelled CleneNanomedicineContingentEarnoutMilestoneThreeSharesCancelled	2503851
CY2021Q4	clnn	Australia Research And Development Credit Receivable AustraliaResearchAndDevelopmentCreditReceivable	1564000
CY2020Q4	clnn	Australia Research And Development Credit Receivable AustraliaResearchAndDevelopmentCreditReceivable	2148000
CY2021Q4	clnn	Cro Prepayments CROPrepayments	194
CY2020Q4	clnn	Cro Prepayments CROPrepayments	1211
CY2021Q4	clnn	Metals To Be Used In Research And Development MetalsToBeUsedInResearchAndDevelopment	2237000
CY2020Q4	clnn	Metals To Be Used In Research And Development MetalsToBeUsedInResearchAndDevelopment	31000
CY2021Q4	clnn	Directors Officers Insurance DirectorsOfficersInsurance	41000
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	169000
CY2020Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	112000
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4205000
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	3502000
CY2021Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	3327000
CY2020Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	3077000
CY2021Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	147000
CY2020Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	147000
CY2021Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	3943000
CY2020Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	3889000
CY2021Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	2052000
CY2020Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	490000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9469000
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7603000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4297000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3378000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5172000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4225000
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	30000
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	189000
CY2021Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	2049000
CY2020Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	1225000
CY2021Q4	clnn	Accrued Cro Fees AccruedCROFees	718000
CY2020Q4	clnn	Accrued Cro Fees AccruedCROFees	788000
CY2021Q4	clnn	Deferred Grant Funds DeferredGrantFunds	520000
CY2020Q4	clnn	Deferred Grant Funds DeferredGrantFunds	301000
CY2021Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	33000
CY2020Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	33000
CY2020Q4	clnn	Accrued Transaction Costs AccruedTransactionCosts	1354000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	260000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	70000
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3610000
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3960000
CY2020Q2	clnn	Remaining Rightofuse Asset RemainingRightofuseAsset	300000
CY2020Q2	clnn	Terminated Operating Lease Liability TerminatedOperatingLeaseLiability	300000
CY2020Q2	clnn	Recognized Gain On Operating Lease RecognizedGainOnOperatingLease	100000
CY2020Q2	clnn	Right Of Use Assets RightOfUseAssets	400000
CY2020Q2	clnn	Leaseholdimprovements Leaseholdimprovements	400000
CY2020Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	800000
CY2021Q3	clnn	Operating Leases Rightof Use Assets OperatingLeasesRightofUseAssets	2400000
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	2400000
CY2021Q3	us-gaap	Incentive To Lessee IncentiveToLessee	1000000.0
CY2021Q4	clnn	Leaseincentiverecordedconstructioninprogress Leaseincentiverecordedconstructioninprogress	500000
CY2021	us-gaap	Lessor Operating Lease Description LessorOperatingLeaseDescription	The lease has an initial ten-year term and provides us the right and option to extend or renew for two periods of five years each. In accordance with ASC 842, the payments to be made in option periods have not been recognized as part of the right-of-use asset or lease liability because we do not assess the exercise of the option to be reasonably certain.
CY2021Q4	clnn	Operating Lease Obligations Weighted Average Interest Rate OperatingLeaseObligationsWeightedAverageInterestRate	0.096
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y1M6D
CY2020Q4	clnn	Operating Lease Obligations Weighted Average Interest Rate OperatingLeaseObligationsWeightedAverageInterestRate	0.096
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y3M18D
CY2021Q4	clnn	Finance Lease Laboratory Equipment Gross FinanceLeaseLaboratoryEquipmentGross	408000
CY2020Q4	clnn	Finance Lease Laboratory Equipment Gross FinanceLeaseLaboratoryEquipmentGross	920000
CY2021Q4	clnn	Finance Lease Furniture And Fixtures Gross FinanceLeaseFurnitureAndFixturesGross	0
CY2020Q4	clnn	Finance Lease Furniture And Fixtures Gross FinanceLeaseFurnitureAndFixturesGross	46000
CY2021Q4	clnn	Finance Lease Work In Process Gross FinanceLeaseWorkInProcessGross	228000
CY2020Q4	clnn	Finance Lease Work In Process Gross FinanceLeaseWorkInProcessGross	228000
CY2021Q4	clnn	Finance Lease Liability Gross FinanceLeaseLiabilityGross	636000
CY2020Q4	clnn	Finance Lease Liability Gross FinanceLeaseLiabilityGross	1194000
CY2021Q4	clnn	Accumulated Depreciation Depletion And Amortization Leases AccumulatedDepreciationDepletionAndAmortizationLeases	-244000
CY2020Q4	clnn	Accumulated Depreciation Depletion And Amortization Leases AccumulatedDepreciationDepletionAndAmortizationLeases	-593000
CY2021Q4	clnn	Finance Lease Liability Net FinanceLeaseLiabilityNet	392000
CY2020Q4	clnn	Finance Lease Liability Net FinanceLeaseLiabilityNet	601000
CY2021Q4	clnn	Finance Lease Obligations Weightedaverage Interest Rate FinanceLeaseObligationsWeightedaverageInterestRate	0.088
CY2021Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P1Y10M24D
CY2020Q4	clnn	Finance Lease Obligations Weightedaverage Interest Rate FinanceLeaseObligationsWeightedaverageInterestRate	0.081
CY2020Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y8M12D
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	82000
CY2020	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	175000
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	27000
CY2020	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	37000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	429000
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	293000
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	73000
CY2020	us-gaap	Short Term Lease Cost ShortTermLeaseCost	249000
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	130000
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	92000
CY2021	us-gaap	Lease Cost LeaseCost	741000
CY2020	us-gaap	Lease Cost LeaseCost	846000
CY2021Q4	clnn	Operating Cash Flows From Operating Leases OperatingCashFlowsFromOperatingLeases	-633000
CY2020Q4	clnn	Operating Cash Flows From Operating Leases OperatingCashFlowsFromOperatingLeases	-635000
CY2021Q4	clnn	Operating Cash Flows From Finance Leases OperatingCashFlowsFromFinanceLeases	-27000
CY2020Q4	clnn	Operating Cash Flows From Finance Leases OperatingCashFlowsFromFinanceLeases	-37000
CY2021Q4	clnn	Finance Cash Flows From Finance Leases FinanceCashFlowsFromFinanceLeases	-152000
CY2020Q4	clnn	Finance Cash Flows From Finance Leases FinanceCashFlowsFromFinanceLeases	-194000
CY2021Q4	clnn	Total Term Loans TotalTermLoans	20736000
CY2020Q4	clnn	Total Term Loans TotalTermLoans	1949000
CY2021Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	1654000
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	-4598000
CY2021	clnn	Total Notes Payable And Convertible Notes Payable TotalNotesPayableAndConvertibleNotesPayable	14484000
CY2020	clnn	Total Notes Payable And Convertible Notes Payable TotalNotesPayableAndConvertibleNotesPayable	1949000
CY2021	clnn	Contingent Consideration Classified As Equity Fair Value Adjustment Earn Out ContingentConsiderationClassifiedAsEquityFairValueAdjustmentEarnOut	18100000
CY2020	clnn	Contingent Consideration Classified As Equity Fair Value Adjustment Earn Out ContingentConsiderationClassifiedAsEquityFairValueAdjustmentEarnOut	52100000
CY2021	clnn	Gain Loss On Clene Nano Medicine Contingents Earnout GainLossOnCleneNanoMedicineContingentsEarnout	34000000.0
CY2020	clnn	Gain Loss On Clene Nano Medicine Contingents Earnout GainLossOnCleneNanoMedicineContingentsEarnout	12700000
CY2021Q4	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	2300000
CY2020Q4	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	5900000
CY2021	clnn	Gain Loss On Initial Shareholders Contingents Earnout GainLossOnInitialShareholdersContingentsEarnout	3600000
CY2020	clnn	Gain Loss On Initial Shareholders Contingents Earnout GainLossOnInitialShareholdersContingentsEarnout	1500000
CY2021Q4	clnn	Clene Nanomedicine Contingent Earnout Milestone Three Shares Cancelled CleneNanomedicineContingentEarnoutMilestoneThreeSharesCancelled	2503851
CY2021Q2	clnn	Changeinfairvaluewarrants Changeinfairvaluewarrants	1500000
CY2021	clnn	Changeinfairvaluewarrants Changeinfairvaluewarrants	1000000.0
CY2021	clnn	Scheduleoffuturepaymentsnetofunamortizeddebtdiscounts Scheduleoffuturepaymentsnetofunamortizeddebtdiscounts	<span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> is a schedule of future payments, net of unamortized debt discounts, if Avenue does not convert up to </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the loan into Common Stock between May 21, 2022 through May 21, 2024:</span><p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:80.028%;"/> <td style="width:1.939%;"/> <td style="width:1.206%;"/> <td style="width:16.03%;"/> <td style="width:0.798%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31, 2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,667</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,333</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2026</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Thereafter</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">—</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Subtotal of future principal payments</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20,000</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less unamortized debt discount associated with issuance date warrant fair value<br/> and financing costs</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,654</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,346</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> </tr> </table>
CY2021Q4	clnn	Debt Instrument Unamortized Discount Year One DebtInstrumentUnamortizedDiscountYearOne	0
CY2021Q4	clnn	Debt Instrument Unamortized Discount Year Two DebtInstrumentUnamortizedDiscountYearTwo	6667000
CY2021Q4	clnn	Debt Instrument Unamortized Discount Year Three DebtInstrumentUnamortizedDiscountYearThree	13333000
CY2021Q4	clnn	Debt Instrument Unamortized Discount Year Four DebtInstrumentUnamortizedDiscountYearFour	0
CY2021Q4	clnn	Debt Instrument Unamortized Discount Year Five DebtInstrumentUnamortizedDiscountYearFive	0
CY2021Q4	clnn	Debt Instrument Thereafter DebtInstrumentThereafter	0
CY2021Q4	clnn	Future Principal Payments FuturePrincipalPayments	20000000
CY2021Q4	us-gaap	Debt Instrument Unamortized Premium DebtInstrumentUnamortizedPremium	1654000
CY2021Q4	us-gaap	Debt Securities DebtSecurities	18346000
CY2020	clnn	Lossinfairvalueofwarrantliability Lossinfairvalueofwarrantliability	14600000
CY2021Q4	clnn	Number Of Shares Issuable NumberOfSharesIssuable	4477045
CY2020Q4	clnn	Number Of Shares Issuable NumberOfSharesIssuable	5566361
CY2021Q4	us-gaap	Shares Issued SharesIssued	2407500
CY2021	clnn	Company Warrant Redemption Right CompanyWarrantRedemptionRight	We may redeem the outstanding warrants, in whole and not in part, at a price of $0.01 per warrant if, and only if, the last sales price of our Common Stock equals or exceeds $16.50 per share for any 20 trading days within a 30-trading day period ending three business days before we send the notice of redemption.
CY2021	clnn	Warrant Redemption Price Per Share WarrantRedemptionPricePerShare	0.01
CY2021Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	16.50
CY2020Q3	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	700000
CY2021	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	482703
CY2020Q3	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	700000
CY2020	clnn	Loss On Derivative Instrument LossOnDerivativeInstrument	29000
CY2020Q4	clnn	Contingent Consideration Classified As Equity Fair Value Adjustment Earn Out ContingentConsiderationClassifiedAsEquityFairValueAdjustmentEarnOut	64700000
CY2020Q4	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	7400000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-6269000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-18985000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-3899000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	114000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10168000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-18871000
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	146000
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	146000
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-282000
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	260000
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-282000
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	260000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-428000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	406000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-2135000
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-3963000
CY2021	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
CY2021	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.03
CY2021	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Amount DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount	4500
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	200000
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1690000
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-917000
CY2021	clnn	Income Tax Reconciliation Warrant Liability IncomeTaxReconciliationWarrantLiability	-206000
CY2020	clnn	Income Tax Reconciliation Warrant Liability IncomeTaxReconciliationWarrantLiability	3069000
CY2021	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	-7884000
CY2020	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	-2966000
CY2021	clnn	Income Tax Reconciliation Nondeductible Expenses Research And Development IncomeTaxReconciliationNondeductibleExpensesResearchAndDevelopment	-640000
CY2020	clnn	Income Tax Reconciliation Nondeductible Expenses Research And Development IncomeTaxReconciliationNondeductibleExpensesResearchAndDevelopment	-425000
CY2021	clnn	Income Tax Reconciliation Stock Compensation IncomeTaxReconciliationStockCompensation	-462000
CY2020	clnn	Income Tax Reconciliation Stock Compensation IncomeTaxReconciliationStockCompensation	147000
CY2021	clnn	Income Tax Reconciliation Foreign Rate Differential IncomeTaxReconciliationForeignRateDifferential	-157000
CY2020	clnn	Income Tax Reconciliation Foreign Rate Differential IncomeTaxReconciliationForeignRateDifferential	7000
CY2021	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	625000
CY2020	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	88000
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	12121000
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	5366000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-428000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	406000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0421
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0215
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	26898000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	17958000
CY2021Q4	clnn	Deferred Tax Liabilities Deferred Expense Depreciation DeferredTaxLiabilitiesDeferredExpenseDepreciation	1478000
CY2020Q4	clnn	Deferred Tax Liabilities Deferred Expense Depreciation DeferredTaxLiabilitiesDeferredExpenseDepreciation	1810000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	2594000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1682000
CY2021Q4	clnn	Deferred Tax Liabilities Lease Liability DeferredTaxLiabilitiesLeaseLiability	1158000
CY2020Q4	clnn	Deferred Tax Liabilities Lease Liability DeferredTaxLiabilitiesLeaseLiability	520000
CY2021Q4	clnn	Deferred Tax Assets Rightof Use Asset DeferredTaxAssetsRightofUseAsset	798000
CY2020Q4	clnn	Deferred Tax Assets Rightof Use Asset DeferredTaxAssetsRightofUseAsset	270000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	0
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	160000
CY2021Q4	clnn	Deferred Tax Assets Tax Deferred Nonqualified Stock Options And Restricted Stock Awards DeferredTaxAssetsTaxDeferredNonqualifiedStockOptionsAndRestrictedStockAwards	2815000
CY2020Q4	clnn	Deferred Tax Assets Tax Deferred Nonqualified Stock Options And Restricted Stock Awards DeferredTaxAssetsTaxDeferredNonqualifiedStockOptionsAndRestrictedStockAwards	146000
CY2021Q4	clnn	Deferred Tax Assets Tax Deferred Accrued Compensation DeferredTaxAssetsTaxDeferredAccruedCompensation	74000
CY2020Q4	clnn	Deferred Tax Assets Tax Deferred Accrued Compensation DeferredTaxAssetsTaxDeferredAccruedCompensation	115000
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	19000
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	-260000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	34238000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	21861000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	34238000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	22121000
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	260000
CY2021	clnn	Research And Development Credit Expiry Term ResearchAndDevelopmentCreditExpiryTerm	Additionally, we have approximately $2.6 million of research and development credit carryforwards that will begin to expire after 2034 if not utilized.
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	100000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12384000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	761000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7032591
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.97
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y4M2D
CY2020Q4	clnn	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValue	62462000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3881122
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.54
CY2021	clnn	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term Granted SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted	P9Y6M7D
CY2021	clnn	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Intrinsic Value Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueGranted	0
CY2021	clnn	Share Based Compensation Arrangement Number Of Options Exercised ShareBasedCompensationArrangementNumberOfOptionsExercised	427444
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.04
CY2021	clnn	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodIntrinsicValue	1310000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	91242
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	8.45
CY2021	clnn	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue	0
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10395027
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.35
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y3M25D
CY2021Q4	clnn	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValue	21082000
CY2021Q4	clnn	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExercisableNumber	6238796
CY2021Q4	clnn	Weighted Average Exercise Price Per Share Option Vested And Exercisable WeightedAverageExercisePricePerShareOptionVestedAndExercisable	1.09
CY2021	clnn	Weighted Average Exercise Price Weighted Average Remaining Term Years Options Vested And Eexercisable Ending WeightedAverageExercisePriceWeightedAverageRemainingTermYearsOptionsVestedAndEexercisableEnding	P4Y4M6D
CY2021Q4	clnn	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Intrinsic Value Intrinsic Value Options Vested And Exercisable Ending ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsIntrinsicValueIntrinsicValueOptionsVestedAndExercisableEnding	20254000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	10395027
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	3.35
CY2021	clnn	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm1	P6Y3M25D
CY2021Q4	clnn	Intrinsic Value Stock Options Vested And Expected To Vest Intrinsic Value Options V IntrinsicValueStockOptionsVestedAndExpectedToVestIntrinsicValueOptionsV	21082000
CY2021	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	4900000
CY2020	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	800000
CY2021	clnn	Unrecognized Stockbased Compensation UnrecognizedStockbasedCompensation	18300000
CY2020	clnn	Unrecognized Stockbased Compensation UnrecognizedStockbasedCompensation	2400000
CY2021	clnn	Sharebased Compensation Arrangement By Sharebased Payment Award Nonvestweighted Average Period Expected Term SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm	P3Y18D
CY2020	clnn	Sharebased Compensation Arrangement By Sharebased Payment Award Nonvestweighted Average Period Expected Term SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm	P2Y14D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.49
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	0
CY2021Q4	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	736000
CY2021Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	474000
CY2021Q4	clnn	Clene Nanomedicine Contingent Earnout Fair Value Disclosure CleneNanomedicineContingentEarnoutFairValueDisclosure	18100000
CY2021Q4	clnn	Initial Shareholders Contingent Earnout Fair Value Disclosure InitialShareholdersContingentEarnoutFairValueDisclosure	2317000
CY2020Q4	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	1296000
CY2020Q4	clnn	Clene Nanomedicine Contingent Earnout Fair Value Disclosure CleneNanomedicineContingentEarnoutFairValueDisclosure	52053000
CY2020Q4	clnn	Initial Shareholders Contingent Earnout Fair Value Disclosure InitialShareholdersContingentEarnoutFairValueDisclosure	5906000
CY2021	clnn	Notes Payable Based On Closing Price NotesPayableBasedOnClosingPrice	4.10
CY2020	clnn	Notes Payable Based On Closing Price NotesPayableBasedOnClosingPrice	9.01
CY2021	clnn	Fairvalueamortizedcost Fairvalueamortizedcost	18300000
CY2021Q4	us-gaap	Notes Payable NotesPayable	13700000
CY2021	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	4600000
CY2021Q4	clnn	Fair Value Of The Conversion Feature FairValueOfTheConversionFeature	800000
CY2020Q4	clnn	Common Stock Issuable Upon Achievement Of Milestones CommonStockIssuableUponAchievementOfMilestones	9096185
CY2021Q4	clnn	Common Stock Issuable Upon Achievement Of Milestones CommonStockIssuableUponAchievementOfMilestones	6592334
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021	clnn	Preferred Stock Share PreferredStockShare	1000000
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	clnn	Issuance Of Common Stock Upon The Reverse Recapitalization IssuanceOfCommonStockUponTheReverseRecapitalization	2303495
CY2020Q4	clnn	Recapitalization Shares RecapitalizationShares	644164
CY2020Q4	clnn	Investor Purchased Shares InvestorPurchasedShares	2239500
CY2020Q4	us-gaap	Share Price SharePrice	10.00
CY2020Q4	clnn	Net Proceed NetProceed	22200000
CY2020	clnn	Private Placement Warrants Description PrivatePlacementWarrantsDescription	In addition, investors in the 2020 PIPE also received warrants to purchase a number of shares equal to one-half of the number of 2020 PIPE shares, totaling 1,119,750 shares of Common Stock, at $0.01 per share and subject to a 180-day holding period (see Note 10).
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	11198
CY2021Q2	clnn	Common Stock Shares Purchased CommonStockSharesPurchased	960540
CY2021Q3	clnn	Purchase Option Units PurchaseOptionUnits	220000
CY2021Q3	clnn	Exercise Price Per Share ExercisePricePerShare	11.50
CY2021Q3	clnn	Net Issuance Shares NetIssuanceShares	54083
CY2021Q3	clnn	Net Issuance Warrants NetIssuanceWarrants	49166
CY2021Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	11.50
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	62312097
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	62312097
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	59526171
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	59526171
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-9740000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-19277000
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	61558455
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	17503992
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.16
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.10
CY2021	clnn	Convertible Stock Warrants ConvertibleStockWarrants	482703
CY2021	clnn	Common Stock Warrants CommonStockWarrants	4477045
CY2020	clnn	Common Stock Warrants CommonStockWarrants	4446613
CY2021	clnn	Options To Purchase Common Stockin Shares OptionsToPurchaseCommonStockinShares	10395027
CY2020	clnn	Options To Purchase Common Stockin Shares OptionsToPurchaseCommonStockinShares	7032591
CY2021	clnn	Unvested Restricted Stock Awards UnvestedRestrictedStockAwards	916603
CY2020	clnn	Unvested Restricted Stock Awards UnvestedRestrictedStockAwards	0
CY2021	clnn	Chardan Unit Purchase Option To Purchase Common Stock ChardanUnitPurchaseOptionToPurchaseCommonStock	0
CY2020	clnn	Chardan Unit Purchase Option To Purchase Common Stock ChardanUnitPurchaseOptionToPurchaseCommonStock	242000
CY2021	clnn	Earnout Sharessee EarnoutSharessee	6592334
CY2020	clnn	Earnout Sharessee EarnoutSharessee	9096185
CY2021	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	22863712
CY2020	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	20817389
CY2018Q3	clnn	Related Party Transaction Royalty Fee Rate For Revenues RelatedPartyTransactionRoyaltyFeeRateForRevenues	0.03
CY2021	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	500000
CY2020	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	100000
CY2021	clnn	Related Party Transaction Proceeds From Product Sales RelatedPartyTransactionProceedsFromProductSales	100000
CY2020	clnn	Related Party Transaction Proceeds From Product Sales RelatedPartyTransactionProceedsFromProductSales	100000
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	0
CY2020Q4	us-gaap	Deferred Revenue DeferredRevenue	100000
CY2021	us-gaap	Proceeds From Royalties Received ProceedsFromRoyaltiesReceived	200000
CY2020	us-gaap	Proceeds From Royalties Received ProceedsFromRoyaltiesReceived	30000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5172000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4225000
CY2021	us-gaap	Revenues Revenues	723000
CY2020	us-gaap	Revenues Revenues	206000
CY2021	us-gaap	Depreciation Depreciation	955000
CY2020	us-gaap	Depreciation Depreciation	963000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12384000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	761000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-49978000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-20214000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-49978000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-20214000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	39810000
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1343000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10168000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-18871000
CY2021Q4	us-gaap	Assets Assets	63063000
CY2020Q4	us-gaap	Assets Assets	68243000
CY2021	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	1332000
CY2020	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	387000
CY2021	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	On August 10, 2021, we entered into an operating lease for laboratory space that replaced a previous operating lease for the same facility. The commencement of the lease and the termination of the previous lease was effective as of February 1, 2022.

Files In Submission

Name	View Source	Status
0000950170-22-003410-index-headers.html	Edgar Link	pending
0000950170-22-003410-index.html	Edgar Link	pending
0000950170-22-003410.txt	Edgar Link	pending
0000950170-22-003410-xbrl.zip	Edgar Link	pending
clnn-20211231.htm	Edgar Link	pending
clnn-20211231.xsd	Edgar Link	pending
clnn-20211231_cal.xml	Edgar Link	unprocessable
clnn-20211231_def.xml	Edgar Link	unprocessable
clnn-20211231_htm.xml	Edgar Link	completed
clnn-20211231_lab.xml	Edgar Link	unprocessable
clnn-20211231_pre.xml	Edgar Link	unprocessable
clnn-ex10_14.htm	Edgar Link	pending
clnn-ex21_1.htm	Edgar Link	pending
clnn-ex23_1.htm	Edgar Link	pending
clnn-ex23_2.htm	Edgar Link	pending
clnn-ex31_1.htm	Edgar Link	pending
clnn-ex31_2.htm	Edgar Link	pending
clnn-ex32_1.htm	Edgar Link	pending
clnn-ex32_2.htm	Edgar Link	pending
clnn-ex4_1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
img179956768_0.jpg	Edgar Link	pending
img179956768_1.jpg	Edgar Link	pending
img179956768_10.jpg	Edgar Link	pending
img179956768_11.jpg	Edgar Link	pending
img179956768_12.jpg	Edgar Link	pending
img179956768_2.jpg	Edgar Link	pending
img179956768_3.jpg	Edgar Link	pending
img179956768_4.jpg	Edgar Link	pending
img179956768_5.jpg	Edgar Link	pending
img179956768_6.jpg	Edgar Link	pending
img179956768_7.jpg	Edgar Link	pending
img179956768_8.jpg	Edgar Link	pending
img179956768_9.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CLNN
Clene Inc. Stock $clnn

2022 Q1 Form 10-K Financial Statement

#000095017022003410 Filed on March 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLNN Clene Inc. Stock $clnn

2022 Q1 Form 10-K Financial Statement

#000095017022003410 Filed on March 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLNN
Clene Inc. Stock $clnn